Absorbable Medical Devices Based on Novel Films and Foams Made From Semi-Crystalline, Segmented Copolymers of Lactide and Epsilon-Caprolactone Exhibiting Long Term Absorption Characteristics
US-2016354510-A1 · Dec 8, 2016 · US
US9896560B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9896560-B2 |
| Application number | US-201514728226-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 2, 2015 |
| Priority date | Jun 2, 2015 |
| Publication date | Feb 20, 2018 |
| Grant date | Feb 20, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Novel absorbable foams, lyophilizing solutions, and lyophilizing and annealing processes are disclosed. The foams are made from copolymers of glycolide and epsilon-caprolactone. The foams are useful in or as implantable medical devices.
Opening claim text (preview).
We claim: 1. An absorbable polymer foam, comprising: a semicrystalline absorbable segmented block copolymer having a random center block segment of repeating units of polymerized glycolide and polymerized epsilon-caprolactone and an end block segment that comprises predominantly polymerized glycolide, wherein the mole ratio of polymerized glycolide to polymerized epsilon-caprolactone of the entire segmented copolymer is between about 55:45 to about 65:35, and having a mole ratio of polymerized glycolide to polymerized epsilon-caprolactone in the random center block segment between about 45:55 to about 52:48, wherein the absorbable polymer foam has a compressive pressure at 2 mm height greater than 1.05 gf/mm 2 after 28 days of incubation in a buffer of pH 7.27 at 37° C. under continuous compression. 2. The foam of claim 1 wherein the copolymer has an inherent viscosity between about 0.5 dL/g and about 2.5 dl/g, as measured in a 0.1 g/dl solution of HFIP at 25° C. 3. The foam of claim 1 having a solid content from about 3 weight percent to about 20 weight percent. 4. The foam of claim 3 having the solid content between about 5 weight percent and 15 weight percent. 5. The foam of claim 1 having a thickness between about 0.5 mm to about 13 mm. 6. The foam of claim 5 having the thickness between about 1 mm and about 5 mm. 7. The foam of claim 1 prepared from 10 weight percent lyophilization solution. 8. The foam of claim 1 having a degradation coefficient less than −0.095 gf/(mm 2 day) when incubated in a buffer of pH 7.27 at 37° C. under continuous compression. 9. The foam of claim 8 prepared from 10 weight percent lyophilization solution. 10. The foam of claim 1 having mechanical integrity at least 30 days post-implantation. 11. The foam of claim 1 having mechanical integrity at least 60 days post-implantation. 12. The foam of claim 1 having a crystallinity level greater than about 10 percent. 13. The foam of claim 1 having a crystallinity level greater than about 20 percent.
Polyesters derived from hydroxy carboxylic acids, e.g. lactones (C08J2367/06 takes precedence) · CPC title
Biodegradable polymers · CPC title
Open cells, i.e. more than 50% of the pores are open · CPC title
the finished foam itself being a gel or a gel being temporarily formed when processing the foamable composition · CPC title
the liquid phase being organic · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.